New Tx for Ovarian Cancer Discovered
Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. A release from the hospital quotes Maureen G. Phipps, MD, MPH, chief of obstetrics and gynecology, as saying, "This is a tremendous discovery and could mean the difference between life or death for some women with ovarian cancer.”
The work coming out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, entitled "HE4 (WFDC2) gene overexpression promotes ovarian tumor growth" was recently published in the international science journal Scientific Reports, a Nature publishing group.
Moore created the Risk of Ovarian Malignancy Algorithm (ROMA) to determine if a pelvic mass is cancerous based on the levels of HE4 and another protein. A release from the hospital quotes him as saying, "We have known that the protein HE4 is present in women who have ovarian cancer. What no one knew was why the protein is there or what activates it."
The release notes that the WFCD2 gene produces a "messenger RNA" that encodes for the HE4 protein, not only imparting an aggressiveness to the tumor, enabling it to grow quickly, but also conveying a resistance to chemotherapy drugs used to treat the tumor.
"It plays a part in allowing the cancer to grow without restriction," Moore says. "We have determined that HE4 plays a part in allowing ovarian cells to become cancer cells, giving them the ability to grow and resist chemo."
Once they identified the function of the protein, Moore's research team was able to design a biologic drug that can prevent the messenger RNA gene from creating HE4. The novel biologic has been tested in cell and animal models, and the results are that the cancer does not grow as aggressively and responds to chemotherapy.
"We would give this biologic – which has minimal side effects – to any patient we identify through a blood test as producing HE4," he says, adding that oncologists have recognized that women with high levels of HE4 do not respond to treatment and their survival rates are lower. "This would be an individualized treatment that could increase survival rates of some women with ovarian cancer."
Moore and his team will continue testing the biologic drug, preparing for clinical trials in humans.